GH Research PLC (NasdaqGM: GHRS)
Health Care · Pharmaceuticals · IE
$28.33
-3.93% today · +132.8% 1Y
GH Research PLC (NasdaqGM: GHRS) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $2.02B and employs 73 people.
Over the last twelve months the share price has gained 132.8%, trading between 11.83 and 31.44.
Tweenvest scores GH Research PLC across four factors: quality 29/100. Its strongest factor is quality.
GHRS price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $2.02B
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -0.99
- Dividend yield
- —
- Beta (5Y)
- 1.29
- 52-week high
- $31.44
- 52-week low
- $11.83
- Avg volume (3M)
- —
- Shares outstanding
- 68.64M
- Employees
- 73
- Next earnings
- —
About GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical firm dedicated to creating novel therapies for psychiatric and neurological conditions. The company primarily concentrates on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) treatments, specifically targeting patients with treatment-resistant depression (TRD). Its most advanced program is GH001, an inhalable 5-MeO-DMT product candidate that has successfully completed two Phase 1 clinical trials and a subsequent Phase 1/2 clinical trial in TRD patients. Additionally, GH Research is developing GH002, an injectable 5-MeO-DMT candidate, and GH003, an intranasal 5-MeO-DMT candidate. Both GH002 and GH003 are currently in preclinical development, with a focus on their potential applications in various psychiatric and neurological disorders. Founded in 2018, GH Research PLC is headquartered in Dublin, Ireland.
- Founded
- 2018
- Listed since
- Jun 25, 2021
- Exchange
- Nasdaq Global Market
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.12T | $1,255.40 | +0.88% |
| Johnson & JohnsonNYSE: JNJ | $651.25B | $270.24 | +1.07% |
| Merck & Co., Inc.NYSE: MRK | $376.37B | $152.55 | +2.39% |
| Roche Holding AGSWX: ROP | $373.91B | CHF375.60 | +1.02% |
| Novartis AGSWX: NOVN | $302.17B | CHF127.42 | +0.85% |
| AstraZeneca PLCLSE: AZN | $258.76B | £122.40 | +1.26% |
| Novo Nordisk A/SCPSE: NOVO B | $207.84B | Dkr300.85 | +1.59% |
| Pfizer Inc.NYSE: PFE | $159.99B | $28.07 | +1.01% |
Figures last refreshed Aug 18, 2026.